Participant sociodemographic characteristics at baseline assessment for each study group
| Characteristics | Control group (n=23) | Handbook group (n=21) | Pharmaceutical counselling group (n=20) | Total (n=64) |
|---|---|---|---|---|
| Patients’ characteristics | ||||
| Age (years) | ||||
| Median (Q25/75) | 10.4 (3.6/15.8) | 5.6 (4.0/13.6) | 6.8 (2.7/14.0) | 6.8 (3.6/14.7) |
| Range | 0.1–18.1 | 0.4–17.6 | 0.2–16.5 | 0.1–18.1 |
| Gender (female), n (%) | 11 (48) | 8 (38) | 7 (35) | 26 (41) |
| Cancer diagnosis, n (%) | ||||
| Haematological | 16 (70) | 9 (43) | 7 (35) | 32 (50) |
| Solid tumour | 6 (26) | 7 (33) | 9 (45) | 22 (34) |
| Other | 1 (4) | 5 (24) | 4 (20) | 10 (16) |
| Drug treatment period (months), median (range) | 5 (0–169) | 13 (0–67) | 8 (0–118) | 10 (0–169) |
| Number of drugs, median (Q25/75) | 4 (2.0/6.0) | 3 (0.8/4.0) | 2.5 (1.0/4.5) | 3 (1.0/4.8) |
| Respondents’ characteristics | ||||
| Respondent to questionnaire, n (%) | ||||
| Patient | 5 (22) | 4 (19) | 3 (15) | 12 (19) |
| Parent | 18 (78) | 17 (81) | 17 (85) | 52 (81) |
| Age (years) | ||||
| Patient, median (range) | 17 (14.8–18.1) | 14.8 (14.7–17.6) | 14.8 (13.7–15.5) | 14.8 (13.7–18.1) |
| Parent, n (%) | ||||
| 18–25 | 0 (0) | 1 (6) | 1 (6) | 2 (4) |
| 26–35 | 7 (39) | 9 (53) | 6 (35) | 22 (42) |
| 36–50 | 11 (61) | 7 (41) | 10 (59) | 28 (54) |
| Gender | ||||
| Patients (female), n (%) | 3 (60) | 3 (75) | 2 (67) | 8 (67) |
| Parents (female), n (%) | 14 (78) | 14 (82) | 13 (76) | 41 (79) |
| Parents’ health-related job (yes), n (%) | 4 (17) | 6 (29) | 2 (10) | 12 (19) |